Michael Asbach

Jan 17, 2025 | psychiatrictimes.com | Arash Javanbakht |Matthew Robinson |Tory Woodard |Michael Asbach

2 Commerce Drive Cranbury, NJ 08512

Jan 10, 2025 | psychiatrictimes.com | Arash Javanbakht |Matthew Robinson |Michael Asbach |Tory Woodard

2 Commerce Drive Cranbury, NJ 08512

Oct 22, 2024 | psychiatrictimes.com | Michael Asbach

Michael Asbach, DMSc, PA-C, Psych-CAQ, shares 3 things he is excited about concerning Cobenfy, and 3 things he will keep an eye on as the new treatment rolls out. The US Food and Drug Administration recently approved Cobenfy, formerly known as KarXT (xanomeline-trospium), a first in-class agent for the treatment of schizophrenia. Cobenfy is the first new agent with a novel mechanism of action for schizophrenia more than 50 years. Excited About... 1. The novel mechanism of action. 2. Fewer side effects.

May 20, 2024 | psychiatrictimes.com | Richard Jackson |Michael Asbach

May 20, 2024Richard Jackson, MD, and Micheal Asbach, DMSc, PA-C, discuss the impact of of tardive dyskinesia (TD) on a caregiver’s life and work, highlighting the need for clinicians to support all allies in their patient’s support network. Brought to you by Teva Medical Affairs. Richard Jackson, MD: But now this similar survey, a similar survey, actually also looked at it from the angle of the caregiver. So what were some of the notable findings from the caregiver survey research?

May 20, 2024 | psychiatrictimes.com | Richard Jackson |Michael Asbach

Brought to you by Teva Medical Affairs. Richard Jackson, MD: Hello. Welcome to this Psychiatric Times™ Between the Lines video series titled Expert Insights on the Impacts of Tardive Dyskinesia on Patient Quality of Life. My name is Richard Jackson. I am an adult, child, and forensic psychiatrist associated with Oakland Beaumont University School of Medicine, Department of Psychiatry, and the University of Michigan School of Medicine, Department of Psychiatry. And joining me today is Michael Asbach.